Author Archives: admin


AKC Canine Health Foundation Releases Webinar … – Stem Cell Cafe

Free Webinar on the Use of Regenerative Medicine to Treat Orthopedic Injuries in Dogs

Raleigh, NC (PRWEB) April 25, 2013

In this free, 40-minute webinar, Dr. Canapp discusses the recent progress in the use of regenerative medicine to treat orthopedic injuries in dogs and also identifies areas where further research is needed. Designed for both lay and scientific audiences, Dr. Canapp explains the different types of therapy that fall under the category of regenerative medicine, while presenting the stories of three canine clients whose lives were drastically improved through this exciting and innovative treatment.

Regenerative medicine has extraordinary potential to change the way we treat both acute injury and chronic disease in dogs. Early evidence shows these techniques have real promise in helping canine patients recover from injury. Our job as a foundation is to fund research that will provide owners and veterinarians with solid evidence-based medicine, said Dr. Shila Nordone, CHF Chief Scientific Officer. We are pleased to partner with Dr. Canapp to share the emerging technology available to dog lovers throughout the world, and we look forward to a long-term research partnership with Dr. Canapp and collaborators to firmly establish best practices with regenerative medicine technology.

For the two week period following the release of the webinar, CHF will be compiling viewer questions which will be answered by Dr. Canapp and posted to the website.

In 2012, CHF established the Canine Athlete Initiative (CAI) which focuses on the health needs of active dogs. The CAI fund provides grants for cutting-edge research into orthopedic concerns, proper nutrition and conditioning to achieve maximum performance while preventing injury, and innovative rehabilitation techniques. Through the CAI, the foundation also educates the public on the joys of participating in canine athletic events, as well as the value of preventive examinations and optimal nutrition to keep all dogs at the top of their game.

Dr. Canapp completed a combined DVM and Masters of Clinical Science in Surgery at Kansas State University. He is a Diplomate of the American College of Veterinary Surgeons and is certified in Canine Rehabilitation, stem cell therapy and tibial-plateau-leveling osteotomy or TPLO surgery. To date, he has performed more than 2000 TPLO procedures to stabilize the stifle joint after ruptures of the cranial cruciate ligament. Dr. Canapp has been named a charter Diplomate in the newly recognized American College of Veterinary Sports Medicine and Rehabilitation (ACVSMR).

CHF HealthE-Barks webinars are released several times each year and feature key opinion leaders in various fields of canine health. To download the free webinar Regenerative Medicine for Canine Orthopedic Conditions, visit http://www.akcchf.org/webinars, or to make a donation to support this and other canine health research, visit http://www.akcchf.org/donate.

CHF is a non-profit organization dedicated to funding research to prevent, treat and cure canine disease. Like CHF on Facebook, follow CHF on Twitter @CanineHealthFnd, or connect with CHF on LinkedIn.

# # #

Original post:
AKC Canine Health Foundation Releases Webinar ... - Stem Cell Cafe

Dr. Farshid Guilak: Can stem cells help those with arthritis? – Stem …

Apr 25

Stems cells taken from just a few grams of body fat are a promising weapon against the crippling effects of osteoarthritis.

For the past two decades, knee, hip or other joint replacements have been the standard treatment for the deterioration of joint cartilage and the underlying bone. But artificial joints only last about 15 years and are difficult to repair once they fail.

Stem cell injections may offer a new type of therapy by either stopping the degenerative process or by regenerating the damaged cartilage, said pioneering researcher Dr. Farshid Guilak, a professor of orthopedic surgery and director of orthopedic research at Duke University.

Guilak, one of the first researchers to grow cartilage from fat, explains why stem cells are a bright light in osteoarthritis research and why widespread clinical use is still years away. Below is an edited transcript of the interview.

Q: How are stem cell injections purported to help?

A: Several studies in animals show that stem cell injections may help by reducing the inflammation in the joint. Stem cells appear to have a natural capacity to produce anti-inflammatory molecules, and once injected in the joint, can slow down the degenerative process in osteoarthritis.

(Since this interview, research published in Stem Cells Translational Medicine has found that stem cells may also be an effective way to deliver therapeutic proteins for pain relief related to rheumatoid arthritis.)

Q: Does the bulk of research look at how stem cells heal traumatic injuries, or does it look at degenerative conditions such as arthritis?

A: Nearly all previous studies on stem cell therapies in joints have focused on trying to repair small focal damage to the cartilage. Only a few recent studies have begun to examine the possibility for treating the whole joint, either to grow enough cartilage to resurface the entire joint or to use stem cells to prevent further degeneration.

Read more:
Dr. Farshid Guilak: Can stem cells help those with arthritis? – Stem ...

Stem Cell Therapy Market in Asia-Pacific to 2018 …

NEW YORK, April 24, 2013 /PRNewswire/ Reportlinker.com announces that a new market research report is available in its catalogue:

Stem Cell Therapy Market in Asia-Pacific to 2018 Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

http://www.reportlinker.com/p01075729/Stem-Cell-Therapy-Market-in-Asia-Pacific-to-2018Commercialization-Supported-by-Favorable-Government-Policies-Strong-Pipeline-and-Increased-Licensing-Activity.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

Stem Cell Therapy Market in Asia-Pacific to 2018 Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

Summary

GBI Research, the leading business intelligence provider, has released its latest research Stem Cell Therapy Market in Asia-Pacific to 2018 Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity. The report provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

GBI Research analysis finds the stem cell therapy market was valued at $545m in 2012, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10% from 2012 to 2018, to attain a value of $972m in 2018. The market is poised for significant growth in the forecast period due to the anticipated launch of JCR Pharmaceuticals JR-031 (2014) in Japan and FCB Pharmicells Cerecellgram (CCG) (2015) in South Korea. The research is mainly in early stages, with the majority of the molecules being in early stages of development (Phase I/II and Phase II). Phase I/II and Phase II contribute 67% of the pipeline. Stem cell research is dominated by hospitals/universities/institutions, which contribute 63% of the molecules in the pipeline. The dominance of institutional research is attributable to uncertain therapeutic outcomes in stem cell research.The major companies conducting research in India include Reliance Life Sciences and Stempeutics Research Pvt Ltd, among others. The major institutions include PGIMER and AIIMS.

Scope

Country analysis of regulatory framework of India, China, South-Korea, Japan and Singapore In-depth information and analysis on the pipeline products expected to bring a shift to the market positions of the leading manufacturers. Market characterization data for stem cell research for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. Key drivers and restraints that have a significant impact on the market. Competitive landscape of stem cell research in Asia-Pacific. The key companies discussed in this report are Stempeutics, Reliance Lifesciences, International Stem cell services, Shenzhen Beike Biotechnology, JCR Pharmaceuticals, ES Cells International, Stem Cell Technologies i, Pharmicell and Medipost Key M&A activities, licensing agreements, that have taken place between stem cell companies in 2007 till date.

Go here to see the original:
Stem Cell Therapy Market in Asia-Pacific to 2018 ...

Hormone Dramatically Increases Insulin Production, Possible Diabetes Breakthrough

Editor's Choice Main Category: Diabetes Article Date: 26 Apr 2013 - 9:00 PDT

Current ratings for: Hormone Dramatically Increases Insulin Production, Possible Diabetes Breakthrough

3.8 (10 votes)

3 (2 votes)

The authors wrote that betatrophin might also help patients with type 1 diabetes, or juvenile diabetes when they are first diagnosed.

In animal experiments the researchers found that betatrophin caused laboratory mice to produce beta cells at up to 30 times the normal rate. Beta cells are the insulin-secreting cells in the pancreas - put simply, beta cells produce insulin.

These new beta cells only produce insulin when the body requires it. The scientists explained that this breakthrough could mean that type 2 diabetes patients may have a natural regulation of insulin, plus a considerable reduction in diabetes-related complications. Diabetes is a major cause of amputations and non-genetic loss of vision.

HSCI Co-Director Doug Melton and postdoctoral fellow Peng Yi, who both discovered betatrophin, stressed that a great deal of work remains to be done before trying the hormone out on humans. They added that their work so far, which was mainly funded by a federal research grant, has already attracted the attention of pharmaceutical and biotech companies.

Doug Melton, who is Harvard's Xander University Professor and co-chair of the University's Department of Stem Cell and Regenerative Biology, said:

Type 2 diabetes prevalence in the USA has increased considerably over the last thirty years, in parallel with rising obesity rates, the authors explained. The illness causes patients to gradually lose beta cells, as well as the ability to produce enough insulin.

Read more from the original source:
Hormone Dramatically Increases Insulin Production, Possible Diabetes Breakthrough

Many Kids Who Undergo Stem Cell Transplants Must Return to Hospital

WEDNESDAY, April 24 (HealthDay News) -- Nearly two-thirds of children who received stem cell transplants were readmitted to the hospital within six months for treatment of problems such as infections and unexplained fevers, a new study finds.

Children who were given stem cells donated by other people were twice as likely to be readmitted as those who received their own stem cells, said the researchers at Dana-Farber/Children's Hospital Cancer Center in Boston.

"No one had ever looked at these data in children," Dr. Leslie Lehmann, clinical director of pediatric stem cell transplantation, said in a cancer center news release. "This is very important information and will allow us to counsel families appropriately, as well as try to devise interventions that reduce the rate of readmissions."

Lehmann and Harvard Medical School student David Shulman analyzed the medical records of 129 children who had stem cell transplants from 2008 to 2011 and found that 64 percent of them had at least one hospital readmission within 180 days after their transplant.

Fever without a known cause accounted for 39 percent of readmissions, infections for 24 percent, and gastrointestinal problems for 15 percent, the study found.

"Most of the patients went on to be successfully treated and ultimately did very well," Lehmann said.

The researchers also found that 79 percent of children who received stem cells from a related or unrelated donor were readmitted, compared with 38 percent of those who received their own stem cells.

The findings are scheduled for presentation at the annual meeting of the American Society of Pediatric Hematology Oncology, taking place this week in Miami. Study data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

"We hope these findings can eventually lead to identifying a group of low-risk children who could be managed at local hospitals rather than transplant centers, reducing costs and inconvenience to families," Lehmann said.

The goal is to identify which patients could be safely treated without requiring hospital admission, she said.

Originally posted here:
Many Kids Who Undergo Stem Cell Transplants Must Return to Hospital

Bubba bounces back! Stem cell treatment for dogs

BACKGROUND: The use of stem cells to treat various health problems in pets first came about in 2003 for the treatment of horses. A few years later, stem cell treatments for household pets, such as dogs and cats, started to become available as an alternative to surgery or more serious procedures. While veterinarians continue to research different applications, so far stem cells are often used in regenerative therapy for dogs in order to help with arthritis and other joint issues. For this purpose, stem cells are taken from the dogs own fat tissue and injected directly into the diseased joints. (Source: http://www.harvardpress.com)

TREATMENT: Stem cell therapy is just one of several alternative treatment options now available for pets. Other alternative veterinary medicine includes acupuncture, traditional Chinese herbal medicine, and chiropractic and aquatic therapies. Acupuncture is the application of small-gauge needles to various points on the body for the purpose of eliciting physiological responses in the treatment of almost any disease or condition. Chinese herbal medicine is mainly used with dogs because it is difficult to administer to cats. The herbs come in powder, capsule, and biscuit form. Powder is the least expensive, but most difficult to give. They are used to treat the same conditions as Western Medicine except for surgical conditions. (Source: http://www.holistic-pet-vet.com/chinese-herbal-medicine-for-pets) These treatments have gained popularity as pet owners have become more and more willing to do whatever it takes to keep their animals healthy. In fact, in 2008 the International Veterinary Acupuncture Society reported that the number of veterinarians who have completed their 156 hour long training course in animal acupuncture has quadrupled over the past decade. (Source: http://www.time.com)

NEW TECHNOLOGY: Veterinarian Ashraf Gomaa from Abbott Animal Hospital in Rehoboth, MA used stem cell therapy to help improve Bubba the bulldogs hip dysplasia. The adipose-derived stem cell procedure performed on Bubba is the first one to be done in the state Massachusetts. Dr. Gomaa extracted fat cells from Bubba and then put them through a machine which breaks the cells down to the healthy stem cells. The stem cells were then injected directly into Bubbas hip. An added benefit to the procedure is that since the animals own fat cells are used, there are no serious side effects associated with the injections. Although stem cell regenerative therapy does not cure hip dysplasia, it can greatly reduce symptoms and improve the animals ability to function. Currently, Dr. Gomaa is the only veterinarian in the area certified to perform this particular procedure. (Source: http://www.abbottanimalhospital.com)

More:
Bubba bounces back! Stem cell treatment for dogs

Health Beat: Stem cell treatment for dogs, cats

From repairing torn ligaments to rebuilding bones, stem cell procedures are helping mankind in many ways. Now, mans best friend is getting in on the action, too.

Bubba, a 2-1/2-year-old English bulldog, was born with severe hip dysplasia that made it difficult and painful for him to walk.

"He's had to be injected once a month the last two years to ease the pain in his joints and the hip bone," said Bob Cook, Bubba's owner.

So when Cook heard about a new stem cell procedure that could relieve Bubbas pain, he jumped at the chance.

Dr. Ashraf Gomaa, veterinarian at Abbott Animal Hospital, extracted fat from Bubba's shoulder. Enzymes were added to the fat. Then, a machine separated the stem cells. Finally, the stem cells were injected back into Bubba to help decrease his painful inflammation.

"You want to inject it as closely as possible to the joint that is affected. Those stem cells react to inflammation and they have an affinity to inflammation so they go to any area of the body that has any type of trauma," Gomaa said.

On average, the doctor said the treatment lasts one to two years and can be repeated as needed.

Cook said it's put the bounce back in Bubbas step and probably saved his life.

"If it wasn't for this, he would probably have been on some serious pain meds and probably wouldnt have lived much longer," said Cook.

The stem cell procedure is approved for dogs and cats. The doctor said dogs or cats with joint, cartilage, tendon or ligament pain are good candidates for the procedure.

See the rest here:
Health Beat: Stem cell treatment for dogs, cats

Explore the Forefront of iPS Cell Research … – Stem Cell Cafe

TOKYO(BUSINESS WIRE)

Expectation toward regenerative medicine and stem cell research represented by iPS cells is ever growing, not only for clinical application but also as tools to make drug development/discovery more effective and efficient. Especially in Japan, home of the Novel prize winner Dr. Yamanaka, the market is moving very actively, gaining support in many aspects such as government subsidies, legislation, launch of research centers and so on.

At BIOtech 2013 Japan (Asias LARGEST bio event taking place in Tokyo from May 8 to 10), there will be an increased number of presentations, research achievements and technologies/products related to iPS Cell Research / Regenerative Medicine showcased. Why not visit BIOtech 2013 Japan and explore the forefront of the hottest field?

The foremost authority of stem cell research addresses the future potential of iPS Cells (CONFERENCE) At the Conference, the latest development on iPS Cells and Regenerative Medicine will be addressed as one of the main features. No.1 popular session at the moment is Special Session-3 spoken by the foremost authority of stem cell research, Dr. Hiro Nakauchi (Professor and Director, Center of Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science of The University of Tokyo). In addition to his presentation iPS Technology and its Potential for Future Medicine, Dr. Sawa (Osaka University Graduate School of Medicine) will disclose newly-developed cell sheet technology and its application for complete regeneration of severely-damaged myocardium. There will be more sessions featuring regenerative medicine and stem cell research, such as Special Session-5 addressing the great challenge of regenerative medicine 3-D Tissue Engineering, Special Session-9 addressing the theme from a different approach materials and manufacturing technologies required for further development of regenerative medicine, and many more. >>Full program & application (FREE admission with Member Registration)

The latest research achievements by Japanese academics (PARTNERING) BIOtech 2013 Japan will also be a prime opportunity to explore the latest academic research achievements and find partners from about 200 Japanese academic presenters, who participate in Partnering at BIOtech 2013 Japan through online Bio Partnering System. There will be an increased number of platform technologies/seeds related to iPS Cells / Regenerative Medicine presented this year. (See below for excerpts) -Screening for compounds using hiPS cells and a chemically defined serum-free culture (NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION, Dr. Masaki Kinehara) -Cancer Stem Cell Model Developed From iPS Cells (OKAYAMA UNIVERSITY, Dr. Masaharu Seno) -Production of virus-free iPS cells by a novel cell penetrating peptide (NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE, Dr. Yukihito Ishizaka) -Development of the biological pacemaker derived from pluripotent stem cells (TOTTORI UNIVERSITY, Dr. Yasuaki Shirayoshi) -Cytometry using antibody arrays for the quality control of stem cells (HIROSHIMA UNIVERSITY, Dr. Koichi Kato)

>>Search other research themes / academics >>Join Bio Partnering System and receive proposals/appointment requests from academics (Member Registration)

Products/services supporting iPS Cell Research (EXHIBITION) Many companies considering the growth of the iPS market as a huge opportunity, theres a notable increase in exhibits for/applied to iPS cell research at BIOtech 2013 Japan. >>Exhibitors with products/services for iPS/ES Cells Research Why not find the latest products/technologies at Asias largest product/technology showcase, where 600 exhibitors gather from around the world? (expected) >>Search exhibitors on e-Guidebook

Visit BIOtech 2013 Japan! (May 8-10 at Tokyo Big Sight) Still in time! To visit, get FREE Invitation Ticket NOW. >>>http://www.bio-t.jp/en/inv/

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130423006972/en/

View post: Explore the Forefront of iPS Cell Research / Regenerative Medicine at Asia's Largest Bio Event, BIOtech 2013 Japan

See the rest here:
Explore the Forefront of iPS Cell Research ... - Stem Cell Cafe

Stem Cell Therapy Market in Asia-Pacific to 2018 – Commercialization Supported by Favorable Government Policies …

NEW YORK, April 24, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

http://www.reportlinker.com/p01075729/Stem-Cell-Therapy-Market-in-Asia-Pacific-to-2018---Commercialization-Supported-by-Favorable-Government-Policies-Strong-Pipeline-and-Increased-Licensing-Activity.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity". The report provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research analysis finds the stem cell therapy market was valued at $545m in 2012, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10% from 2012 to 2018, to attain a value of $972m in 2018. The market is poised for significant growth in the forecast period due to the anticipated launch of JCR Pharmaceuticals' JR-031 (2014) in Japan and FCB Pharmicell's Cerecellgram (CCG) (2015) in South Korea. The research is mainly in early stages, with the majority of the molecules being in early stages of development (Phase I/II and Phase II). Phase I/II and Phase II contribute 67% of the pipeline. Stem cell research is dominated by hospitals/universities/institutions, which contribute 63% of the molecules in the pipeline. The dominance of institutional research is attributable to uncertain therapeutic outcomes in stem cell research.The major companies conducting research in India include Reliance Life Sciences and Stempeutics Research Pvt Ltd, among others. The major institutions include PGIMER and AIIMS.

Scope

- Country analysis of regulatory framework of India, China, South-Korea, Japan and Singapore - In-depth information and analysis on the pipeline products expected to bring a shift to the market positions of the leading manufacturers. - Market characterization data for stem cell research for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. - Key drivers and restraints that have a significant impact on the market. - Competitive landscape of stem cell research in Asia-Pacific. The key companies discussed in this report are Stempeutics, Reliance Lifesciences, International Stem cell services, Shenzhen Beike Biotechnology, JCR Pharmaceuticals, ES Cells International, Stem Cell Technologies i, Pharmicell and Medipost - Key M&A activities, licensing agreements, that have taken place between stem cell companies in 2007 till date.

Excerpt from:
Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies ...